WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

 

List of new DDDs decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDDs will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

 

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs Implementation in ATC/DDD index if no objection is received
J05AH04laninamivir40mgInhal.powder01.02.20192020
J01MA12levofloxacin0.24gInhal.solution01.02.20192020
A04AD11nabilone3mgO01.02.20192020
A16AX09glycerol phenylbutyrate15gO01.02.20192020
G04BX15pentosan polysulfate sodium0.3gO01.02.20192020
J04AA03calcium aminosalicylate15gO01.02.20192020
J05AP06asunaprevir0.2gO01.02.20192020
J05AP10elbasvir50mgO01.02.20192020
J05AP11grazoprevir0.1gO01.02.20192020
J05AX26amenamevir0.4gO01.02.20192020
J05AX27favipiravir1.6gO01.02.20192020
L02BB05apalutamide0.24gO01.02.20192020
M03BX03pridinol6mgO01.02.20192020
V03AE10sodium zirconium cyclosilicate7.5gO01.02.20192020
A10BJ06semaglutide0.11mgP01.02.20192020
A16AB17cerliponase alfa21mgP01.02.20192020
J04AB06enviomycin1gP01.02.20192020
J05AB03vidarabine0.7gP01.02.20192020
J05AH03peramivir0.6gP01.02.20192020
L04AB07opinercept7mgP01.02.20192020
L04AC12brodalumab15mgP01.02.20192020
N02CX07erenumab2.5mgP01.02.20192020

Last updated: 2018-11-21